Market capitalization | $374.42m |
Enterprise Value | $178.74m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 6.08 |
P/S ratio (TTM) P/S ratio | 12.74 |
P/B ratio (TTM) P/B ratio | 1.50 |
Revenue growth (TTM) Revenue growth | 83.26% |
Revenue (TTM) Revenue | $29.38m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
8 Analysts have issued a C4 Therapeutics Inc forecast:
8 Analysts have issued a C4 Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 29 29 |
83%
83%
|
|
Gross Profit | 22 22 |
169%
169%
|
|
EBITDA | -109 -109 |
20%
20%
|
EBIT (Operating Income) EBIT | -116 -116 |
19%
19%
|
Net Profit | -108 -108 |
23%
23%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Andrew Hirsch |
Employees | 145 |
Founded | 2015 |
Website | www.c4therapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.